TACSTD2 and neoplasm: Up to date, therapeutic strategies against Trop-2 have been extensively explored to either inhibit Trop-2 mediated tumor invasion or metastasis with solely employed anti-Trop-2 antibodies or facilitate drug delivery to tumor sites specifically with ADC formats, and most of the pre-clinical or clinical investigation focus on the development of ADC against Trop-2.